A NASH play­er touts pos­i­tive PhI­II da­ta, but true test still lies ahead

Af­ter years in which de­vel­op­ers faced an es­sen­tial­ly un­break­able stone wall for non-al­co­holic steato­hep­ati­tis (NASH), an ad­vanced form of non-al­co­holic fat­ty liv­er dis­ease (NAFLD), an­oth­er biotech is ap­proach­ing the wall and look­ing to see whether it can break through — with some new Phase III da­ta.

NASH play­er Madri­gal Phar­ma­ceu­ti­cals an­nounced this morn­ing that they have topline clin­i­cal da­ta for their drug resme­tirom, a thy­roid hor­mone re­cep­tor (THR) β-se­lec­tive ag­o­nist, in a place­bo-con­trolled, dou­ble-blind Phase III tri­al for NAFLD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER